BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BCTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $26.72M
- EPS (TTM)
- -$6.97
- Dividend yield
- None
- 52-week range
- 2.60 – 13.09
- Day range
- 3.02 – 3.20
- Volume / Avg
- 109.66K / 250.81K
- Beta
- —
- Shares outstanding
- 8.73M
- Next earnings
- Dec 10, 2026
52-week range
BCTX stock today
On Nov 20, BCTX ended the session at $3.06, shedding $0.105 (3.32%), versus the S&P 500's 3.70% decline. Trading was light, with 109.66K shares changing hands, about 44% of the average daily volume. Shares are 76.6% below their 52-week high of $13.09, set on Dec 9, 2025 and 17.7% above the 52-week low of $2.60, near the bottom of the past year's range.
BCTX is down 57.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.7%. BriaCell Therapeutics has posted a net loss over the last twelve months (EPS of -$6.97), so its P/E ratio is not meaningful. The company is scheduled to report Oct/2026 results on Dec 10.
Summary generated from market data by MetaCap's automated system. Methodology
About BriaCell Therapeutics
Company profileBriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. William V. Williams FCPA, M.D.
- Headquarters
- West Vancouver, BC
- Website
- briacell.com
Financial highlights
Full financialsBriaCell Therapeutics reported a net loss of $34.9 million, compared with a loss of $26.3 million a year earlier. Diluted earnings per share came in at -$6.97.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-34.90M | $-26.31M | $-4.79M | $-20.30M | $-26.84M |
| EPS (diluted) | $-6.97 | $-62.19 | $-43.68 | $-1.30 | $-1.73 |
Earnings
Earnings history- Next report
- Dec 10, 2026
- Last reported (Jul/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-1.24 vs —
BCTX news
All BCTX news- Healthcare Stocks Advance: OBX Surges 38%, ONCO Gains 32%, TMDX Rises 26%NasdaqBCTX, DAVI, OBX, ONCO
- BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026GlobeNewswire
- BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast CancerGlobeNewswire
BriaCell Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TELOTelomir Pharmaceuticals Inc. | 0.364 | -17.24% | $26.82M | vs BCTX |
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs BCTX |
| EDSAEdesa Biotech Inc. | 2.00 | -8.05% | $27.02M | vs BCTX |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs BCTX |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs BCTX |
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs BCTX |
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs BCTX |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs BCTX |
Indexes, lists and sector
BriaCell Therapeutics stock FAQ
What is BriaCell Therapeutics's stock price today?
BCTX last traded at $3.06 as of Nov 20, 4:00 PM EST, down 3.32% on the day. Prices are delayed at least 15 minutes.
Does BriaCell Therapeutics pay a dividend?
No. BriaCell Therapeutics does not currently pay a regular cash dividend.
When is BriaCell Therapeutics's next earnings date?
BriaCell Therapeutics is expected to report earnings on Thursday, December 10, 2026.
Who is BriaCell Therapeutics's CEO?
Dr. William V. Williams FCPA, M.D. is the chief executive officer of BriaCell Therapeutics Corp..
Has BCTX ever split its stock?
Yes. The most recent BCTX stock split was a 1-for-10 split on Aug 25, 2025, one of 3 splits on record.
What is the BCTX 52-week high?
The 52-week high for BCTX is $13.09 and the 52-week low is $2.60. The stock is currently 76.6% below its high.